Product Images Rizatriptan Benzoate

Figure 1 shows the Kaplan-Meier plot of the probability over time of obtaining headache response (no or mild pain) following treatment with rizatriptan benzoate or placebo. The averages displayed are based on pooled data from 4 placebo-controlled, outpatient trials providing evidence of efficacy (Studies 1, 2, 3, and 4). Patients taking additional treatment or not achieving headache response prior to 2 hours were censored at 2 hours. The chart displays the estimated probability of response based on the hours post-dose and the percentage rates for achieving an initial headache response. The data is presented for Placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg.*

This is a figure and table that show the estimated probability of patients taking a second dose of Rizatriptan Benzoate or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled studies 1, 2, 3, and 4. The plot is based on data obtained in 4 placebo-controlled outpatient clinical trials and includes both patients who had headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.*

This appears to be a table showing the percentage of a certain substance (possibly the drug Rizatriptan Benzoate) at different time intervals (0, 2, and 15 hours) between a placebo and orally disintegrating tablets. The table also includes a 95% confidence interval for the data presented. The purpose of the study is not specified.*

Rizatriptan Benzoate Tablets, USP is a medication available in two strengths: 2 tablets or 4 or 3 tablets. It requires a prescription to be purchased and is produced by a pharmaceutical company with the identifier NG 65862.509-12. The text also includes some unreadable characters.*